TRex Bio, Inc. TRXB
13.67 USD -0.43 (-3.05%)
At closeNov 13, 2026, 4:00 PM EST
13.67 0.00 0.00%
After hours · Nov 13, 4:00 PM ET
13.32 Day range 14.10
12.99 52-week range 15.50
- YTD
- -2.36%
- 1 year
- -2.36%
News
benzinga.com Trex Bio Q3 EPS $(10.06) Trex Bio (NASDAQ:TRXB) reported quarterly losses of $(10.06) per share . This is a 32.72 percent decrease over losses of $(7.58) per share from the same period last year.
globenewswire.com TRexBio Reports Third Quarter 2026 Financial Results and Recent Business Highlights Positive Phase 1a results for TRB-061 support proof of mechanism, with topline Phase 1b data in atopic dermatitis expected in mid-2027 TRB-071 advancing through IND-enabling studies, with Phase 1…- benzinga.com Evercore ISI Group Initiates Coverage On Trex Bio with Outperform Rating, Announces Price Target of $28 Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on Trex Bio (NASDAQ:TRXB) with a Outperform rating and announces Price Target of $28.
benzinga.com This X-Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday New coverage: Pony AI Overweight/$10, X-Energy Outperform/$17, TRex Bio Buy/$39, NuScale Underperform/$5.
benzinga.com JP Morgan Initiates Coverage On Trex Bio with Overweight Rating, Announces Price Target of $20 JP Morgan analyst Brian Cheng initiates coverage on Trex Bio (NASDAQ:TRXB) with a Overweight rating and announces Price Target of $20.
benzinga.com Stifel Initiates Coverage On Trex Bio with Buy Rating, Announces Price Target of $39 Stifel analyst Alex Thompson initiates coverage on Trex Bio (NASDAQ:TRXB) with a Buy rating and announces Price Target of $39.
benzinga.com Wedbush Initiates Coverage On Trex Bio with Outperform Rating, Announces Price Target of $30 Wedbush analyst Martin Fan initiates coverage on Trex Bio (NASDAQ:TRXB) with a Outperform rating and announces Price Target of $30.
benzinga.com Eli Lilly Takes 19.9% Stake In TRex Bio With 5.48M Shares, Investing $12.3M In IPO The Reporting Person beneficially owns an aggregate of 5,480,872 shares of Common Stock of the Issuer, consisting of (a) 2,510,411 shares of Common Stock that were issued to the Reporting Person upon…